High dose chemotherapy and autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: Emerging questions, newer agents, and changing paradigm
Primary treatment for adult and pediatric patients with Hodgkin lymphoma (HL) using current multiagent anthracycline-based chemotherapy with or without radiation therapy will cure approximately >70% of the patients; >95% for early stage with a favorable risk profile and 70–75% with advanced st...
Main Author: | Saad Akhtar |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-12-01
|
Series: | Hematology/Oncology and Stem Cell Therapy |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1658387617300468 |
Similar Items
-
CURRENT ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
by: Luca Castagna, et al.
Published: (2015-02-01) -
Outcomes of Refractory and Relapsed Hodgkin Lymphoma With Autologous Stem-Cell Transplantation: A Single Institution Experience
by: Rabia Wali, et al.
Published: (2019-11-01) -
Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
by: Anna Sureda, et al.
Published: (2020-11-01) -
New agents in relapsed/refractory Hodgkin's lymphoma
by: Irene Biasoli, et al. -
Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation
by: Eva Domingo-Domènech, et al.
Published: (2020-05-01)